

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009139 A1

(51) International Patent Classification⁷: A61L 2/08

Landing Road, Montgomery Village, MD 20886 (US).
DROHAN, William, N. [US/US]; 8417 Oakford Lane,
Springfield, VA 22152 (US).

(21) International Application Number:
PCT/US2003/022450

(74) Agents: FLESHNER, Mark, L. et al.; Fleshner & Kim,
LLP, P.O. Box 221200, Chantilly, VA 20153-1200 (US).

(22) International Filing Date: 18 July 2003 (18.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/197,246 18 July 2002 (18.07.2002) US

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): CLEAR-
ANT, INC. [US/US]; Suite 650, 11111 Santa Monica
Boulevard, Los Angeles, CA 90025 (US).

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (for US only): MANN, David, M.
[US/US]; 7430 Brenish Drive, Gaithersburg, MD 20879
(US). BURGESS, Wilson, H. [US/US]; 12824 Great
Oak Lane, Clifton, VA 20124 (US). KENT, Randall,
S. [US/US]; 3512 Radcliffe, Thousand Oaks, CA 91360
(US). MACPHEE, Martin, J. [CA/US]; 9971 Lake

Published:
— with international search report

[Continued on next page]

(54) Title: METHODS FOR STERILIZING RECOMBINANT OR TRANSGENIC MATERIAL



(57) Abstract: Methods are disclosed for sterilizing biological products to reduce the level of active biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites.

WO 2004/009139 A1



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

METHODS FOR STERILIZING RECOMBINANT OR TRANSGENIC MATERIAL**BACKGROUND OF THE INVENTION****Field of the Invention**

5 The present invention relates to methods for sterilizing biological materials to reduce the level of active biological contaminants therein, such as viruses, bacteria, yeasts, molds, mycoplasmas and/or parasites.

Background of the Invention

10 Several products that are prepared from human, veterinary or experimental use may contain unwanted and potentially dangerous contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites. Consequently, it is of utmost importance that any biologically active contaminant in the product be inactivated before the product is used. This is especially critical when the product is to be administered directly to a patient, for example in blood transfusions, organ
15 transplants and other forms of human therapies. This is also critical for various biotechnology products which are grown in media which contain various types of plasma and which may be subject to mycoplasma or other viral contaminants.

 Previously, most procedures have involved methods that screen or test products for a particular contaminant rather than removal or inactivation of the contaminant from the product.
20 Products that test positive for a contaminant are merely not used. Examples of screening procedures include the testing for a particular virus in human blood from blood donors. Such procedures, however, are not always reliable and are not able to detect the presence of viruses in very low numbers. This reduces the value or certainty of the test in view of the consequences associated with a false negative result. False negative results can be life threatening in certain
25 cases, for example in the case of Acquired Immune Deficiency Syndrome (AIDS). Furthermore, in some instances it can take weeks, if not months, to determine whether or not the product is contaminated.

 More recent efforts have focused in methods to remove or inactivate contaminants in the products. Such methods include heat treating, filtration and the addition of chemical inactivants or
30 sensitizers to the product. Heat treatment requires that the product be heated to approximately 60°C for about 70 hours which can be damaging to sensitive products. Heat inactivation can destroy up to 50% of the biological activity of the product. Filtration involves filtering the product in order to physically remove contaminants. Unfortunately this method may also remove products that have a high molecular weight. Further, in certain cases small viruses may not be removed by the

filter because of the larger molecular structure of the product. The procedure of chemical sensitization involves the addition of noxious agents which bind to the DNA/RNA of the virus and which are activated either by UV or ionizing radiation to produce free radicals which break the chemical bonds in the backbone of the DNA/RNA of the virus or complex it in such a way that the virus can no longer replicate. This procedure requires that unbound sensitizer is washed from cellular products since the sensitizers are toxic, if not mutagenic or carcinogenic, and can not be administered to a patient.

Irradiating a product with gamma radiation is another method of sterilizing a product. Gamma radiation is effective in destroying viruses and bacteria when given in high total doses (Keathly et al., "Is There Life After Irradiation? Part 2," BioPharm July-August, 1993, and Leitman, Use of Blood Cell Irradiation in the Prevention of Post Transfusion Graft-vs-Host Disease," Transfusion Science 10:219-239 (1989)). The published literature in this area, however, teaches that gamma radiation can be damaging to radiation sensitive products, such as blood. In particular, it has been shown that high radiation doses are injurious to red cells, platelets and granulocytes (Leitman). U.S. Patent No. 4,620,908 discloses that protein products must be frozen prior to irradiation in order to maintain the viability of the protein product. This patent concludes that "[i]f the gamma irradiation were applied while the protein material was at, for example, ambient temperature, the material would be also completely destroyed, that is the activity of the material would be rendered so low as to be virtually ineffective." Unfortunately, many sensitive biologicals, such as blood, would lose viability and activity if subjected to freezing for irradiation purposes and then thawing prior to administration to a patient.

In view of the difficulties discussed above, there remains a need for methods of sterilizing biological materials that are effective for reducing the level of active biological contaminants without an adverse effect on the biological material.

25

SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide methods of sterilizing biological materials by reducing the level of active biological contaminants without adversely effecting the biological material. Other objects, features and advantages of the present invention will be set forth in the detailed description of preferred embodiments that follows, and in part will be apparent from the description or may be learned by practice of the invention. These objects and advantages of the invention will be realized and attained by the compositions and methods particularly pointed out in the written description and claims hereof.

In accordance with these and other objects, a first embodiment of the present invention is

directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.

5 A second embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) adding to a biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.

10 A third embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; (ii) adding to the biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (iii) irradiating the biological material with
15 radiation at an effective rate for a time effective to sterilize the biological material. According to this embodiment, steps (i) and (ii) may be reversed.

BREIF DESCRIPTION OF DRAWINGS

FIGURES 1 and 2 are graphs showing the protective effects of certain stabilizers on
20 lyophilized anti-insulin monoclonal antibody exposed to 45 kGy of low dose gamma irradiation.

FIGURES 3A-3C are graphs showing the protective effects of certain stabilizers on lyophilized anti-insulin monoclonal antibody exposed to 45 kGy of low dose gamma irradiation.

FIGURE 4 is a graph showing the protective effects of primary lyophilizing and secondary lyophilizing on the sensitivity of a monoclonal antibody.

25 FIGURE 5 is a graph showing the protective effect of freeze-drying and/or an added stabilizer on the activity of Factor VIII.

FIGURE 6 is a graph showing the protective effects of certain stabilizers on liquid or lyophilized antithrombin III exposed to 25 kGy of low dose gamma irradiation.

30 FIGURES 7-14 are graphs showing the protective effect of certain stabilizers on the activity of lyophilized anti-insulin monoclonal antibody.

FIGURE 15 is a graph showing the protective effect of stabilizers on the activity of lyophilized anti-insulin monoclonal antibody when the sample was irradiated at a high dose rate (30 kGy/hr).

FIGURE 16 is a graph showing the effect of a stabilizer on lyophilized thrombin that was

irradiated with gamma radiation.

FIGURE 17 is a graph showing the effect of a stabilizer on 1gM activity after irradiation with gamma radiation.

FIGURE 18 is a chromatogram showing the effects of gamma irradiation on albumin.

5 FIGURE 19 is a graph showing the protective effects of lyophilization and/or the presence of a stabilizer on thrombin activity after irradiation with gamma radiation.

FIGURES 20-25 are graphs showing the protective effects of certain stabilizers on liquid IVIG polyclonal antibody exposed to 45 kGy of gamma irradiation (1.8 kGy/hr).

10 FIGURE 26 is a graph showing the effects of pH on the recovery of urokinase (liquid or lyophilized) irradiated in the presence of a stabilizer

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

A. Definitions

15 Unless defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the relevant art. All patents and publications mentioned herein are expressly incorporated by reference.

As used herein, the term "biological material" is intended to mean any substance derived or obtained from a living organism. Illustrative examples of biological materials include, but are not limited to, the following: cells; tissues; blood or blood components; proteins, including recombinant and transgenic proteins; botanicals; foods and the like. Preferred examples of biological materials include, but are not limited to, the following: ligaments; tendons; nerves; bone, including demineralized bone matrix, grafts, joints, femurs, femoral heads, etc.; teeth; skin grafts; bone marrow, including bone marrow cell suspensions, whole or processed; heart valves; cartilage; corneas; arteries and veins; organs for transplant, such as hearts, lungs, liver, kidney, intestine, pancreas, limbs and digits; lipids; carbohydrates; collagen (native, afibrillar, atelomeric, soluble and insoluble); chitin and its derivatives including chitosan and its derivatives including NO-carboxy chitosan (NOCC); stem cells, islet of langerhans cells, and other cellular transplants, including genetically altered cells; red blood cells; white blood cells, including monocytes and stem cells; and platelets.

30 As used herein, the term "sterilize" is intended to mean a reduction in the level of at least one active biological contaminant found in the biological material being treated according to the present invention.

As used herein, the term "biological contaminant" is intended to mean a contaminant that, upon direct or indirect contact with a biological material, may have a deleterious effect on a

biological material. Such biological contaminants include the various viruses, bacteria and parasites known to those of skill in the art to generally be found in or infect biological materials such as whole blood or blood components. Examples of biological contaminants include, but are not limited to, the following: viruses, such as human immunodeficiency viruses and other retroviruses, herpes viruses, 5 parainfluenzaviruses, cytomegaloviruses, hepatitis viruses (including hepatitis B and hepatitis C), pox viruses, toga viruses, Epstein-Barr virus and parvoviruses; bacteria, such as Escherichia, Bacillus, Clostridium, Streptococcus and Staphylococcus; parasites, such as Trypanosoma and malarial parasites, including Plasmodium species; yeasts; molds; mycoplasmas; and prions. As used herein, the term "active biological contaminant" is intended to mean a biological contaminant 10 that is capable of causing the deleterious effect.

As used herein, the term "blood components" is intended to mean one or more of the components that may be separated from whole blood and include, but are not limited to, cellular blood components, such as red blood cells, white blood cells and platelets; blood proteins, such as blood clotting factors, enzymes, albumin, plasminogen, fibrinogen and immunoglobulins; and liquid 15 blood components, such as plasma and plasma-containing compositions.

As used herein, the term "cellular blood component" is intended to mean one or more of the components of whole blood that comprises cells, such as red blood cells, white blood cells or platelets.

As used herein, the term "blood protein" is intended to mean one or more of the proteins 20 that are normally found in whole blood. Illustrative examples of blood proteins found in mammals (including humans) include, but are not limited to, coagulation proteins (both vitamin K-dependent, such as Factor VII or Factor IX, and non-vitamin K-dependent, such as Factor VIII and von Willebrand factor), albumin, lipoproteins (high density lipoproteins and/or low density lipoproteins), complement proteins, globulins (such as immunoglobulins IgA, IgM, IgG and IgE), and the like. A preferred group of blood proteins include Factor I (Fibrinogen), Factor II (Prothrombin), Factor III 25 (Tissue Factor), Factor IV (Calcium), Factor V (Proaccelerin), Factor VI (Accelerin), Factor VII (Proconvertin, serum prothrombin conversion), Factor VIII (Antihemophilic factor A), Factor IX (Antihemophilic factor B), Factor X (Stuart-Prower Factor), Factor XI (Plasma thromboplastin antecedent), Factor XII (Hageman Factor), Factor XIII (Protansglutamidase), von Willebrand Factor (vWF), Factor Ia, Factor IIa, Factor Va, Factor VIa, Factor VIIa, Factor VIIIa, Factor IXa, 30 Factor Xa, and Factor XIIIa.

As used herein, the term "liquid blood component" is intended to mean one or more of the fluid, non-cellular components of whole blood, such as plasma (the fluid, non-cellular portion of the blood of humans or animals as found prior to coagulation) or serum (the fluid, non-cellular portion of

the blood of humans or animals after coagulation).

As used herein, the term "a biologically compatible solution" is intended to mean a solution to which biological materials may be exposed, such as by being suspended or dissolved therein, and remain viable, i.e., retain their essential biological and physiological characteristics. Such biologically compatible solutions preferably contain an effective amount of at least one anticoagulant.

As used herein, the term "a biologically compatible buffered solution" is intended to mean a biologically compatible solution having a pH and osmotic properties (e.g. tonicity, osmolality and/or oncotic pressure) suitable for maintaining the integrity of biological materials. Suitable biologically compatible buffered solutions typically have a pH between 5 and 8.5 and are isotonic or only moderately hypotonic or hypertonic. Biologically compatible buffered solutions are known and readily available to those of skill in the art.

As used herein, the term "stabilizer" is intended to mean a compound or material that reduces any damage to the biological material being irradiated to a level that is insufficient to preclude the safe and effective use of that material. Illustrative examples of stabilizers include, but are not limited to, the following: antioxidants, such as ascorbic acid and tocopherol; and free radical scavengers, such as ethanol. Preferred examples of stabilizers include, but are not limited to, the following: fatty acids, including 6,8-dimercapto-octanoic acid (lipoic acid) and its derivatives and analogues (alpha, beta, dihydro, bisnor and tetranor lipoic acid), thiocetic acid, 6,8-dimercapto-octanoic acid, dihydrolopoate (DL-6,8-dithiooctanoic acid methyl ester), lipoamide, bisonor methyl ester and tetranor dihydrolipoic acid, furan fatty acids, oleic and linoleic and palmitic acids and their salts and derivatives; flavonoids, phenylpropanoids, and flavenols, such as quercetin, rutin and its derivatives, apigenin, aminoflavone, catechin, hesperidin and, naririgin; carotenes, including beta-carotene; Co-Q10; xanthophylls; polyhydric alcohols, such as glycerol, mannitol; sugars, such as xylose, glucose, ribose, mannose, fructose and trehalose; amino acids, such as histidine, N-acetylcysteine (NAC), glutamic acid, tryptophan, sodium carpryl N-acetyl tryptophan and methionine; azides, such as sodium azide; enzymes, such as Superoxide Dismutase (SOD) and Catalase; uric acid and its derivatives, such as 1,3-dimethyluric acid and dimethylthiourea; allopurinol; thiols, such as glutathione and cysteine; trace elements, such as selenium; vitamins, such as vitamin A, vitamin C (including its derivatives and salts such as sodium ascorbate and palmitoyl ascorbic acid) and vitamin E (and its derivatives and salts such as tocopherol acetate and alpha-tocotrienol); chromanol-alpha-C6; 6-hydroxy-2,5,7, 8-tetramethylchromna-2 carboxylic acid (Trolox) and derivatives; extraneous proteins, such as gelatin and albumin; tris-3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186); citiolone; pueracetin; chrysin; dimethyl sulfoxide (DMSO); piperazine

diethanesulfonic acid (PIPES); imidazole; methoxypsoralen (MOPS); 1,2-dithiane-4,5-diol; reducing substances, such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT); cholesterol; probucol; indole derivatives; thimerosal; lazaroid and tirilazad mesylate; proanthrenols; proanthocyanidins; ammonium sulfate; Pegorgotein (PEG-SOD); N-tert-butyl-alpha-phenylnitronone (PBN); and 4-hydroxy-2,2,6,6-Tetramethylpiperidin-1 -oxyl (Tempol)

As used herein, the term "residual solvent content" is intended to mean the amount of freely-available liquid in the biological material. Freely-available liquid means that liquid, such as water or an organic solvent (e.g. ethanol, isopropanol, polyethylene glycol, etc.), present in the biological material that is not bound to or complexed with one or more of the non-liquid components of the biological material (e.g. proteins, metal ions or salts, etc.). Freely-available liquid includes intracellular water. The residual solvent contents referenced herein refer to levels determined by the FDA approved, modified Karl Fischer method (Meyer and Boyd, Analytical Chem., 31, 215-219, 1959; May, et al., J. Biol. Standardization, 10, 249-259, 1982; Centers for Biologics Evaluation and Research, FDA, Docket No. 89D-0140, 83-93; 1990).

As used herein, the term "sensitizer" is intended to mean a substance that selectively targets viral, bacterial, and/or parasitic contaminants, rendering them more sensitive to inactivation by radiation, therefore permitting the use of a lower rate of radiation and/or a shorter time of irradiation than in the absence of the sensitizer. Illustrative examples of suitable sensitizers include, but are not limited to, the following: psoralen and its derivatives and analogs (including 3-carboethoxy psoralens); angelicins, khellins and coumarins which contain a halogen substituent and a water solubilization moiety, such as quaternary ammonium ion or phosphonium ion; nucleic acid binding compounds; brominated hematoporphyrin; phthalocyanines; purpurins; porphorins; halogenated or metal atom-substituted derivatives of dihematoporphyrin esters, hematoporphyrin derivatives, benzoporphyrin derivatives, hydrodibenzoporphyrin dimaleimide, hydrodibenzoporphyrin, dicyano disulfone, tetracarbethoxy hydrodibenzoporphyrin, and tetracarbethoxy hydrodibenzoporphyrin dipropionamide; doxorubicin and daunomycin, which may be modified with halogens or metal atoms; netropsin; BD peptide, 52 peptide; S-303 (ALE compound); dyes, such as hypericin, methylene blue, eosin, fluoresceins (and their derivatives), flavins, merocyanine 540; photoactive compounds, such as bergapten; and SE peptide.

As used herein, the term "proteinaceous material" is intended to mean a cellular material that comprises at least one protein or peptide. This material is preferably composed primarily of protein(s) and/or peptide(s). It may be a naturally occurring material, either in its native state or following processing/purification and/or derivatization. It may be artificially produced, either by chemical synthesis or utilizing recombinant/transgenic technology. Such artificially produced

material may also be processed/purified and/or derivatized. Illustrative examples of proteinaceous materials include, but are not limited to, the following: proteins/peptides produced from tissue culture; milk (dairy products); ascites; hormones; growth factors; materials, including pharmaceuticals, extracted or isolated from animal tissue (such as heparin and insulin) or plant matter; plasma (including fresh, frozen and freeze-dried); fibrinogen, fibrin and/or fibrin sealant products; whole blood; protein C; protein S; alpha-1 anti-trypsin (alpha-1 protease inhibitor); butylcholinesterase; anticoagulants, such as coumarin drugs (warfarin); streptokinase; tissue plasminogen activator (TPA); erythropoietin (EPO); urokinase; neupogen; antithrombin-3; alpha-glucosidase; (Fetal) Bovine Serum/Horse Serum; meat; immunoglobulins, including anti-sera, 5 monoclonal antibodies, polyclonal antibodies and genetically engineered or produced antibodies; albumin; alpha-globulins; beta-globulins; gamma-globulins; coagulation proteins; complement proteins; and interferons.

As used herein, the term "ionizing radiation" is intended to mean radiation of sufficient energy to ionize (produce ions) the irradiated biological material. Types of ionizing radiation include, 15 but are not limited to, the following: (i) corpuscular (streams of subatomic particles such as neutrons, electrons, and/or protons); and (ii) electromagnetic (originating in a varying electromagnetic field, such as radio waves, visible and invisible light, x-radiation, and gamma rays).

B. Particularly Preferred Embodiments

20 A first preferred embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.

25 A second embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) adding to a biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (ii) irradiating the biological material with radiation at an effective rate for a time effective to sterilize the biological material.

30 A third embodiment of the present invention is directed to a method for sterilizing a biological material that is sensitive to ionizing radiation comprising: (i) reducing the residual solvent content of a biological material to a level effective to protect the biological material from ionizing radiation; (ii) adding to the biological material at least one stabilizer in an amount effective to protect the biological material from ionizing radiation; and (iii) irradiating the biological material with

radiation at an effective rate for a time effective to sterilize the biological material. The order of steps (i) and (ii) may, of course, be reversed as desired.

The biological material sterilized in accordance with the methods of the present invention may be any material obtained or derived from a living or deceased organism, including a solid
5 material or liquid material or a suspension of any solid(s) in any liquid(s) or a coating of any solid or liquid on a biological or non-biological substrate.

According to the methods of the present invention, the residual solvent content of the biological material is reduced prior to irradiation of the biological material with ionizing radiation. The residual solvent content is reduced to a level that is effective to protect the biological material
10 from the ionizing radiation. Suitable levels of residual solvent content may vary depending upon the nature and characteristics of the particular biological material being irradiated and can be determined empirically by one skilled in the art. Preferably, when the solvent is water, the residual solvent content is less than about 2.0%, more preferably less than about 1.0%, even more preferably less than about 0.5% and most preferably less than about 0.2%.

15 While not wishing to be bound by any theory of operability, it is believed that the reduction in residual solvent content reduce the degrees of freedom of the biological material and thereby protects it from the effects of the ionizing radiation. Similar results might therefore be achieved by lowering the temperature of the biological material below its eutectic point or below its freezing point to likewise reduce the degrees of freedom of the biological material. These results permit the
20 use of a higher rate of irradiation than might otherwise be acceptable.

The residual solvent content of the biological material may be reduced by any of the methods and techniques known to those skilled in the art for removing solvent from a biological material. A particularly preferred method for reducing the residual solvent content of a biological material is lyophilization. According to a particularly preferred embodiment of the present invention,
25 a biological material which has been lyophilized is stored under vacuum or an inert atmosphere (preferably a noble gas, such as helium or argon, more preferably a higher molecular weight noble gas, and most preferably argon) prior to irradiation.

The ionizing radiation employed in the present invention may be any ionizing radiation effective for the inactivation of one or more biological contaminants of the biological material being
30 treated. Preferably the ionizing radiation is electromagnetic radiation and a particularly preferred form of ionizing radiation is gamma radiation.

According to the methods of the present invention, the biological material is irradiated with the ionizing radiation at a rate effective for the inactivation of one or more biological contaminants of the biological material. Suitable rates of irradiation may vary depending upon the particular form

of ionizing radiation and the nature and characteristics of the particular biological material being irradiated and the particular biological contaminants being inactivated. Suitable rates of irradiation can be determined empirically by one skilled in the art. Preferably, the rate of irradiation is constant for the duration of the sterilization procedure.

5 According to a particularly preferred embodiment of the present invention, the rate of irradiation is not more than about 3.0 kGy/hour, more preferably between about 0.1 kGy/hr. and 3.0 kGy/hr, even more preferably between about 0.25 kGy/hr and 2.0 kGy/hour, still even more preferably between about 0.5 kGy/hr and 1.5 kGy/hr and most preferably between about 0.5 kGy/hr and 1.0 kGy/hr.

10 According to another particularly preferred embodiment of the present invention, the rate of irradiation is at least about 3.0 kGy/hr., more preferably at least about 6 kGy/hr., even more preferably at least about 16 kGy/hr., and most preferably at least about 30 kGy/hr.

 The biological material is irradiated with the ionizing radiation for a time effective for the inactivation of one or more biological contaminants of the biological material. Suitable ionization
15 times may vary depending upon the particular form and rate of ionizing radiation and the nature and characteristics of the particular biological material being irradiated and the particular biological contaminants being inactivated. Suitable ionization times can be determined empirically by one skilled in the art.

 Optionally, an effective amount of at least one sensitizer is added to the biological material
20 prior to irradiation with ionizing radiation. Suitable sensitizers are known to those skilled in the art.

 According to methods of the present invention, the irradiation of the biological material may occur at any temperature which is not deleterious to the biological material being treated. According to a preferred embodiment, the biological material is irradiated at ambient temperature. According to an alternate preferred embodiment, the biological material is irradiated at reduced temperature,
25 preferably at or below the eutectic point of the biological material.

C. Examples

 The following examples are illustrative, but not limiting, of the present invention. Other suitable modifications and adaptations are of the variety normally encountered by those skilled in
30 the art and are fully within the spirit and scope of the present invention.

Example 1 - Sterilization of Blood

 A 200 ml bag of one day old packed red blood cells was used. Ethanol was added to the cells in order to achieve a final ethanol concentration of 0.0.1% v/v. The red blood cells were diluted

by a factor of one in ten using a modified Citrate Phosphate Dextrose (CPD) solution having a pH of about 6.4 to 6.7 and having the following composition in a total volume of 500 ml:

	Citrate Acid Monohydrate	0.2g
	Sodium Citrate Dihydrate	27.3g
5	Sodium Monobasic Phosphate	2.2g
	Sodium Dibasic Phosphate	1.0g
	Dextrose	3 .2g

The cells were irradiated in a commercial size gamma irradiator which contained a cobalt
10 60 source rack. Irradiation was done off carrier in an unprotected box. The cells were irradiated for twenty-four hours at a rate of approximately 1 kGy/hr. After the irradiation period the red blood cells were examined visually and were found to be viable, having a brilliant red color. A control sample, consisting of packed red blood cells that were not diluted with the above-described CPD solution, was not viable after irradiation.

15 Four days after the irradiation procedure, the diluted cells were tested for levels of various blood components and the results are shown in Table 1. The control sample consisted of blood from the same bag as the test sample but it did not undergo irradiation. Table 1 illustrates that dilution and irradiation of human blood cells did not significantly alter the white blood cell count. The platelet count and hematocrit values were slightly lower than the control; however, these values are
20 still within the range that is seen in normal adult blood. The level of hemoglobin was higher than in the control indicating that some red blood cells did lyse during the procedure. This is also evidenced by the lower red blood cell count. Nevertheless, contrary to what has been previously published, up to 50 kGy of radiation did not destroy the components of blood by the present procedure. The cells were also counted and found to be viable after 25 kGy of gamma irradiation
25 delivered at a low dose rate of 1 kGy/hr.

TABLE 1

Component	Irradiated Blood	Control Blood
White Blood Cells	4 K/mm ³	4.8 K/mm ³
Red Blood Cells	3 Mi/mm ³	7.2 Mi/mm ³
Hemoglobin	42 g/dl	21 g/dl
Hematocrit	46%	64%
Platelet	100 k/mm ³	120 k/mm ³

Example 2 - Sterilization of Dextrose

Dextrose (or glucose) containing solutions are used in the treatment of carbohydrate and fluid depletion, in the treatment of hypoglycemia, as a plasma expander, in renal dialysis and to counteract hepatotoxins (The Merck Index, Eleventh Edition, Merck & Co., Inc. (1989), and Martindale's Extra Pharmacopoeia, p.1, 265). Dextrose is also the preferred source of carbohydrate in parental nutrition regimens (The Merck Index, Eleventh Edition, Merck & Co., Inc. (1989), and Martindale's Extra Pharmacopoeia, p.1, 265). In all of the above applications, the dextrose must be sterilized before use. Sterilization of dextrose-containing products is generally done by heat sterilization or autoclaving. Unfortunately, these methods have been reported to degrade or caramelize dextrose-containing solutions resulting in a color change in the solution (Martindale's Extra Pharmacopoeia p.1, 265). Gamma irradiation of glucose has also been reported to decompose glucose-containing solutions (Kawakishi, et al., "Radiation-Induced Degradation of D-glucose in Anaerobic Condition," Agric. Biol. Chem., June 1977). Therefore, there is a need for a method that can sterilize dextrose-containing products that does not degrade the product itself. In view of the problems of the prior art, a dextrose solution was treated according to the method of the present invention as follows.

A 5% dextrose solution was irradiated for 24 hours, at a rate of approximately 1 kGy/hr. After irradiation, the product was tested and it was found that there was no visible light spectrum change as compared to the non-irradiated control. Therefore, the present method can be useful in sterilizing products that contain dextrose.

In addition to the above experiment, fresh solutions of 5% and 50% dextrose were irradiated to 25 kGy over 36 hours at ambient temperature. The results were similar to those described above. In addition, UV/VIS scans were obtained and demonstrated a complete absence of the peak at 283.4 nm for "furfural" as per U.S.P. In contrast, dextrose samples sterilized using an autoclave contain the 283.4 nm furfural peak. "Furfurals" are carcinogenic.

Example 3-Sterilization of Human Serum Albumin

Normal Human Serum Albumin was irradiated as a 25% salt-poor solution to a total dose of 25 kGy over 36 hours using a Gammacell 220 (Co⁶⁰ is the gamma ray source in this instrument). The temperature was not controlled during the irradiation but it is estimated that the container holding the albumin solution was approximately 23 °C. The results of HPLC analysis are given in Table 2.

Table 2

Parameter	Control (%)	Irradiated (%)
Polymer	2	3
Dimer	7	8
Monomer	90	86
Low Molecular Weight	1	3
pH	7.05	6.97
NTU (must be > 20)	11.4	11.4

As the results demonstrate, Normal Human Serum Albumin can safely be irradiated to 25 kGy (at a rate of approximately 0.7 kGy/hr) at room temperature without adversely affecting the essential properties of the protein. This has not been demonstrated before. All other attempts at irradiating serum albumin require that it be irradiated in the frozen stage. This adds to the cost and difficulty of doing the irradiation.

10 **Example 4**

Normal human blood from a healthy donor was taken in a heparinized tube, washed three times with standard CPD solution, then diluted 1:20 with CPD containing 0.01% v/v Ethanol. This latter solution of CPD with 0.01% v/v Ethanol is called SCPD. Two ml aliquots were then placed in 10 ml plastic test tubes and irradiated to different doses up to 26 kGy over 36 hours at room temperature. There was no haemolysis and the cells appeared intact if somewhat large and slightly irregular in shape. The results of three separate experiments are reported in Table 3.

TABLE 3

PARAMETER	RCB ¹	HGB ²	HCT ³	MCV ⁴	MCH ⁵	MCHC ⁶	RDW	Flags
1*	1.08	41	.097	89.5	38.3	427	17.7	Nearly Normal
Control	.99	33	0.89	90.2	33.0	366	15.3	
2*				95.0	32.3	339	12.0	
Control								
1	1.22	45	.166	135.8	36.5	269	27.3	1+ Anisocytosis
12 kGy	1.38	45	.199	144.7	33.0	228	24.9	3+ Macrocytosis
1	1.04	32	.169	163.0	31.3	152	18.8	1+ Anisocytosis
16 kGy	0.54	29	.088	162.5	54.5	335	18.8	3+ Macrocytosis
2	0.82	27	.128	156.5	32.8	209	19.8	2+ Anisocytosis
16 kGy	0.81	26	.124	152.6	32.4	212	20.2	3+ Macrocytosis
1	0.79	244	.125	158.4	30.8	194	19.4	1+ Anisocytosis
20 kGy	1.26	28	.203	161.5	22.1	137	19.0	3+ Macrocytosis
2	0.93	30	.141	151.5	32.3	213	20.1	2+ Anisocytosis
20 kGy	0.92	30	.143	155.5	32.1	207	20.5	3+ Macrocytosis
1	1.15	34	.180	155.9	29.4	189	19.1	1+ Anisocytosis
26 kGy	1.15	34	.176	153.0	29.9	195	23.4	3+ Macrocytosis

* Experiment 1 and Experiment 2

¹ Red Blood Cell Count: Cells x 10¹²/liter

² Hemoglobin: grams/liter

³ Hematocrit

⁴ Mean Corpuscular Volume: Femtoliters

⁵ Mean Corpuscular Hemoglobin: picograms

⁶ Mean Corpuscular Hemoglobin Concentration: grams/liter

The cells were easily put into suspension and reconstituted in fresh buffer.

The following three experiments (Examples 5, 6 and 7) were conducted in order to determine the efficacy of the method when treating HIV-contaminated blood. In each Example the cells were similarly treated. In these experiments, the cells were gently agitated after 12, 16 and 24 hours of irradiation. Further, in the third experiment (Example 7), the cells were placed in T25 flasks to provide greater surface area and reduce the concentration due to settling in the bottom of the centrifuge tubes. In each case, the cells were irradiated at a dose rate of approximately 0.7 kGy/hr.

Example 5 - Sterilization of HI V-containing Blood

The following experiments were undertaken with the following specific objectives:

1. To evaluate the toxicity of the process towards red blood cells (RBCs).
2. To evaluate the anti-retroviral activity of the process.

Method

Initially, 2 ml of anticoagulated blood was obtained from an HIVseronegative donor. The blood was centrifuged, and the plasma was removed. The remaining cell pellet was resuspended in 10 ml of the CPD buffer and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 40 ml of the SCPD buffer, and distributed into plastic tubes in 2 ml aliquots, with 16 separate aliquots being retained for further manipulation. For 8 of these tubes, an aliquote of HTLV-IIIB was added. This is a laboratory strain of the HIV virus and 100 tissue culture infective doses (TCID) were added to each of the tubes to be infected. For the remaining 8 tubes, a "mock" infection was performed, by adding a small amount of non-infectious laboratory buffer, phosphate buffered saline (PBS). Four infected and four non-infected tubes were subjected to the process. For comparison, the remaining 8 tubes (four infected and four non-infected) were handled in an identical manner, except that they were not subjected to the process.

It should be stated that at the beginning of the study, a separate aliquot of blood was obtained from the donor. This was processed in the clinical hematology laboratory and a complete hemogram was performed. These baseline results were compared to repeat testing on the study aliquots, which included evaluation of four processed and four unprocessed samples, all of which were not infected with HIV.

An aliquot of 0.5 ml of each of the infected study samples was inoculated on mononuclear cells (MCs) which had been obtained three days earlier. These cells had been suspended in RPMI culture medium, with 10% fetal calf serum and other additives (penicillin, streptomycin, glutamine and HEPES buffer) along with 1 µg/ml PHA-P. At the same time as this inoculation, the cells were

resuspended in fresh medium with rIL-2 (20 U/ml). The cultures were maintained for 7 days. Twice weekly, a portion of the culture medium was harvested for the measurement of HIV p24 antigen levels (commercial ELISA kit, Coulter Electronics, Hialeah, FL) for the measurement of viral growth.

A separate aliquot of the eight infected study samples was used for viral 20 titration experiments. Briefly, serial four-fold dilutions of the virus-containing fluids (ranging from 1:16 to 1:65,536) were inoculated in triplicate in 96-well flat-bottom tissue culture plates. PHA-stimulated MCs were added to each well (4 million cells in 2 ml culture medium, with IL-2). An aliquot of the supernatant from each culture well was harvested twice weekly for the measurement of HIV p24 antigen levels. A well was scored as "positive" if the HIV p24 antigen value was > 30 pg/ml.

The viral titer was calculated according to the Spearman-Kärber method (See ACTG virology protocol manual) using the following equation:

$$M = xk + d[0.5 - (1/n)r]$$

M: titer (in log 4)

xk: dose of highest dilution

d: space between dilutions

n: number of wells per dilution

r: sum of total number of wells.

Results

Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 4.

Table 4

Sample/Number	MCV	MCH	MCHC
Baseline	94.5	32.0	339
Unprocessed-1	91.4	34.4	376
Unprocessed-2	90.2	37.9	420
Unprocessed-3	92.1	40.0	433
Unprocessed-4	91.0	40.2	442
Processed-1	133.4	37.8	284
Processed-2	131.5	45.0	342
Processed-3	128.5	38.9	303
Processed-4	131.1	39.4	301

The abbreviations in Table 4 are explained under Table 3.

As described above, HIV cultures were established using 0.5 ml aliquots of unprocessed and processed study samples. P24 antigen levels (pg/ml) from the study samples on day 4 and day 7 of culture are shown in Table 5.

5

Table 5

Sample/Number	P24 Day 4	P24 Day 7
Unprocessed-1	1360	484
Unprocessed-2	1180	418
Unprocessed-3	1230	516
Unprocessed-4	1080	563
Processed-1	579	241
Processed-2	760	303
Processed-3	590	276
Processed-4	622	203

Finally, one unprocessed sample and one processed sample were selected for the performance of direct viral titration without culture. The results are shown in Table 6.

10

Table 6

Sample/Number	Titer (log 10 ml)
Unprocessed-1	1.5
Processed-1	0.0

The red blood cells were minimally affected by the process, although some reproducible macrocytosis was observed. Although on co-culturing of processed samples, there appeared to be some residual live virus, this was not confirmed by direct titration experiments.

15

Example 6

The objective of this experiment was to evaluate the toxicity of the process towards red blood cells in a comprehensive manner.

20

Method

For this experiment, 1 ml of anticoagulated blood was obtained from the same HIV-seronegative donor as in the first experiment. The blood was centrifuged and the plasma was removed. The remaining cell pellet was resuspended in 10 ml of the CPD buffer and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 20 ml of the SCPD buffer and distributed into plastic tubes in 2 ml aliquots with all 10 aliquots being retained for further manipulation. Eight tubes were subjected to the process, while the final two tubes were retained as control, unprocessed tubes. After the processing, all the tubes were centrifuged, and the resulting pellet was resuspended in 100 μ l buffer. A complete hemogram was performed on these reconcentrated study samples.

As in the first experiment, a separate aliquot of blood was obtained from the donor when the study sample was taken. A complete hemogram was performed on this baseline sample. As the study samples were re-concentrated to 33-50% of their original state, more direct comparisons with the baseline sample could be undertaken than were possible in our earlier experiment.

Results

Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 7. The abbreviations used in Table 7 are defined in Table 3.

Table 7

Sample/Number	RBC	HGS	MCV	MCH	MCHC
Baseline	4.76	152	94.9	31.9	336
Unprocessed-1	0.99	33	90.2	33.0	366
Unprocessed-2	1.08	41	89.5	38.3	427
Processed-1	1.15	34	153.0	29.9	195
Processed-2	1.15	34	155.9	29.4	189
Processed-3	1.26	28	161.5	22.1	137
Processed-4	0.79	24	158.4	30.8	194
Processed-5	0.54	29	162.5	54.5	335
Processed-6	1.04	32	163.0	31.3	192
Processed-7	1.35	45	144.7	33.0	228
Processed-8	1.22	45	135.8	36.5	269

There was macrocytosis of the cells which was present in all the processed samples. Comparable hemoglobin levels were measured in the unprocessed and processed samples. The absolute values were appropriate for the residual dilution. The red blood cells are preserved.

Example 7

Method

For this experiment, 5 ml of anticoagulated blood was obtained from the same HIV-seronegative donor as in the first two experiments. The blood was centrifuged, and the plasma was removed. The remaining cell pellet was resuspended in 100 ml of the CPD buffer, and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 100 ml of the SCPD buffer and distributed in 25 ml aliquots, in T25 tissue culture flasks, with all four aliquots being retained for further manipulation. Two flasks were subject to the process, while the other two were retained as control, unprocessed flasks. After the processing, the contents of each of the flasks was observed and a visual determination of the cells' capacity to absorb oxygen (turning a brighter red on exposure to ambient air) was made. Following this, the contents of the flasks were aspirated and centrifuged, with the residual pellet resuspended in a small volume of buffer. A complete hemogram was performed on these reconcentrated study samples.

As in Examples 5 and 6, a separate aliquot of blood was obtained from the donor when the study sample was taken. A complete hemogram was performed on this baseline sample. As the study samples were re-concentrated to 33-50% of their original state, direct comparisons of a number of specific parameters would be possible with the baseline sample.

Results

On visual inspection, there were no appreciable differences between the processed and unprocessed study samples. Specifically, there appeared to be a uniform distribution of well suspended cells. On exposure to ambient air, the contents of all flasks became somewhat brighter red. No specific quantitative measurements of oxygenation were made.

Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 8. The abbreviations used in Table 8 are defined under Table 3.

Table 8

Sample/Number	RBC	HGS	MCV	MCH	MCHC
Baseline	4.75	153	95.0	32.3	339
Unprocessed-1	0.93	30	151.5	32.3	213
Unprocessed-2	0.92	30	155.5	32.1	207
Processed-1	0.82	27	156.5	32.8	209
Processed-2	0.81	26	152.6	32.4	212

- 5 This experiment was designed to more closely approximate conditions of red blood cells to be transfused into a patient, and was consequently conducted at higher volumes. On a preliminary basis, it does not appear that the process impairs the red blood cells' ability to carry oxygen, although this should be measured more formally. Interestingly, in this experiment, there was no difference in cell size between the processed and unprocessed samples, both being large compared to baseline. Comparable hemoglobin levels were measured in all the study samples.
- 10

Example 8

In this experiment, Immunoglobulin G(IgG) was irradiated in lyophilized form.

15 Method

The results of HPLC analysis of IgG are given in Table 9. As the results demonstrate, the product appears to be unaffected after being irradiated to a dose of 25 kGy at room temperature when the irradiation is delivered at a rate of approximately 0.7 kGy/hr. This has not been previously demonstrated.

20

Table 9

Parameter	Control (%)	Irradiated (%)
Polymer (must be > 2%)	1	1
Dimer	10	13
Monomer	88	84
Low Molecular Weight	1	2

Results

The results presented by Gergely, et al, using freeze dried IgG showed that a portion of the protein was insoluble after an irradiation dose of 12 kGy to 25 kGy at standard irradiation dose rates. (Gergely, J., et al., "Studies of GamaRay-Irradiated Human Immunoglobulin G." SM-92/12 I.A.E.A.) In contrast, using the present method at a dose rate of approximately .7 kGy/hr, none of the protein was insoluble. This would indicate that little or no change or degradation of the protein occurred. Further, Gergely, et al., found that a liquid formulation of human IgG lost all of its activity after irradiation. In studies using the present method on intravenous immunoglobulin (IVIg) in liquid form, it was shown that greater than 70% of a specific antibody in hyperimmune IVIg was retained.

Example 9

In this experiment, alpha I proteinase inhibitor and fibrinogen were irradiated in lyophilized form.

Method

The samples were placed in a Gammacell 220 and irradiated according to the present process to a total dose of 25 kGy. Samples were then returned to the laboratory for analysis. The dose rate was 0.72 kGy/hr.

Results

The alpha I proteinase inhibitor, both treated and control, were 40% of a standard normal pooled plasma sample. The Mancini radial immunodiffusion technique was used as the assay.

The topical fibrinogen complex vials were reconstituted in 10 ml of water. Protamine sulphate vials were reconstituted in 10 ml of water. Protanaine sulphate at a concentration of 10 mg/ml was added to the samples. There was instant formation of monomer in all three preparations.

Example 10

In this experiment, Factors VII, VIII and IV were irradiated in lyophilized form.

Method

The samples were placed in a Gamacell 220 and irradiated to various total doses at a dose rate of approximately 1 kGy/hr.

Results

Factor VII retained 67% activity at 20 kGy and 75% at 10 kGy. Factor VIII retained 77% activity at 20 kGy and 88% at 10 kGy. Similarly, Factor IV showed an activity level of 70% at 20
5 kGy and 80% at 10 kGy.

Excellent results were found for the three Factors. To our knowledge, no one has been able to achieve these results by irradiating the Factors at ambient temperature to such a high dose of radiation with such little loss of activity. This is in direct contrast with the results of Kitchen, et al., "Effect of Gamma Irradiation on the Human Immunodeficiency Virus and Human Coagulation
10 Proteins," Vox Sang 56:223-229 (1989), who found that "the irradiation of lyophilized concentrates is not a viable procedure." Similarly, Hiemstra, et al., "Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors," Transfusion 31:32-39(1991), also concluded that "Gamma radiation must be disregarded as a method for the sterilization of plasma and plasma-derived products, because of the low reduction of virus infectivity at radiation
15 doses that still give acceptable recovery of biologic activity of plasma components."

Example 11

In this experiment, red blood cells were irradiated at a dose rate of 0.5 kGy/hr for periods of time ranging from 7.5 to 90 minutes in order to remove bacterial contaminants.
20

Method

Red blood cells were collected from a healthy donor in EDTA, washed 3 times with CPD solution and resuspended in DPC to provide a 1:20 dilution based on the original blood volume. The cell suspension was then subdivided into 14 tubes. To seven of the tubes, approximately 1.0×10^4 Staphylococcus epidermidis were added. The cells were placed on ice for transport to the
25 irradiation facility. All of the samples were placed in the chamber at ambient temperature and irradiated at 0.5 kGy/hr for periods of time to give total doses of 0.625, 0.125, 0.250, 0.375, 0.500 and 0.750 kGy, respectively. The samples were removed and agitated at each time point and placed on ice for transport either to the microbiology lab or the hematology lab for analysis.

30

Results

The results of the microbiology assays are given in Table 10.

Table 10

Radiation Dose (kGy)	Time (Min.)	Number Surviving
0		92,200
0.625	7.5	84,500
0.125	15	35,000
0.250	30	10,067
0.375	45	1,800
0.500	60	250
0.750	90	0

5 Thus, a dose of 0.75 kGy provides a 4.5 log₁₀ reduction in bacterial survivors. This represents a significant safety factor for blood. Further, the D₁₀ value is approximately 0.125 kGy which corresponds well with the values reported in the literature for similar species of staphylococcus (B.A. Bridges, "The effect of N-Ethylmaleimide on the radiation sensitivity of bacteria," *J. Gen. Microbiol.* 26:467-472 (1962), and Jacobs, G.P. and Sadeh, N.,
 10 "Radiosensitization of *Staphylococcus aureus* by p-hydroxybenzoic acid," *Int. J. Radiat. Biol.* 41:351-356 (1982).

In order to demonstrate that the red blood cells remained viable after the irradiation process, the following parameters were determined for the cells, WBC, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. These determinations merely enumerated the number of
 15 cells present. All nucleated cells would, of course, be inactivated by the radiation dose delivered. The other red blood cell parameters monitored are listed in Table 11. The Methaemoglobin value was unchanged from that of the controls even after a radiation dose of 0.75 kGy. This experiment demonstrates that red blood cells can be safely irradiated by the present method to a dose of 0.75 kGy at room temperature with no loss of cell function.

20

Table 11

Red Blood Cell Values as a Function of Radiation Dose Received

Parameter	Total Dose (in kGy)					
	Whole Blood	0	0.625	0.125	0.250	0.500
RBC	5.06	1.49	1.27	1.77	1.73	1.43
HGB	153	43	41	56	56	46
HTC	.483	.142	.120	.156	.163	1.31
MCV	95.5	95.6	94.3	94.2	93.7	32.1
MCH	31.2	31.1	32.2	31.7	32.2	32.5
MCHC	327	325	341	336	344	353
RDW	13.93	12.1	12.7	12.9	12.9	13.2
METHgB	0.9	0.3	0.3	0.3	0.0	0.9

5 Example 12

This experiment was conducted using the method in Example 11 to confirm the findings of Example 11 and to expand upon some of the parameters measured. The results of this experiment are given in Table 12.

Results

10

Table 12

Red Blood Cell Values as a Function of Radiation Dose Received

Parameter	Total Dose (in kGy)						
	0	0.625	0.125	0.250	0.375	0.555	0.750
HGB	1.8	1.7	1.8	1.7	2.0	2.0	2.0
% O	96.6	96.5	96.2	96.3	96.4	96.5	96.0
% CO	1.0	1.2	1.6	1.3	1.7	1.5	1.5
% NET	0.5	0.5	-0.5	0.4	-0.2	0.4	0.8
% Reduced	1.9	1.9	2.7	2.4	3.2	1.7	1.7
P60 (mm Hg)	34	nd	nd	nd	nd	nd	24
Hill Coefficient	2.1	nd	nd	nd	nd	nd	1.8

nd = not done

The uncertainty with the methaemoglobin levels is $\pm 2\%$; with the p50 it is $\pm 4\%$ (95% confidence).

These results confirm the previous results and indicate that indeed, red blood cells can be irradiated to a dose sufficient to provide 4.5 log₁₀ reduction in bacterial count.

It is contemplated that future experiments will provide similar results for platelet. Thus, with
5 little or no additional manipulation, and without the addition of extraneous materials, red blood cells can be treated by the present process to provide a bacteriologically safe product, thus further reducing the risk of untoward reactions in recipients.

Example 13

10 In this experiment, the protective effects of certain stabilizers were evaluated using lyophilized anti-insulin monoclonal antibody exposed to 45 kGy of low dose, gamma irradiation. The stabilizers tested were: sodium ascorbate, methionine, and lipoic acid.

Method

15 In 2 ml glass vials, 0.5 ml total volume was lyophilized containing 50µg anti-insulin monoclonal anti-body, 5 mg bovine serum albumin (1%) and either no stabilizer or 50mM of the stabilizer of interest. The samples were stoppered under vacuum. Samples were irradiated with gamma radiation (45 kGy total dose, dose rate 1.83 kGy/hr, temperature 4°C) and then reconstituted with water. Antibody binding activity of independent duplicate samples was
20 determined by a standard ELISA protocol: 96-well microtitre plates were coated overnight with 2.5 µg/ml insulin antigen. Three-fold serial dilutions of anti-insulin monoclonal antibody samples starting at 5 µ/ml were used. Goat anti-mouse Ig conjugated to phosphatase used at 50 µg/ml. Sigma 104 alkaline phosphatase substrate was used at 1 mg/ml in DEA buffer. Binding activity was determined by absorbance at 405-620nm.

25 Relative protection was determined by estimating the shift in the titration curve (i.e. concentration of antibody needed to observe the same amount of binding) of the irradiated sample compared to an unirradiated sample at approximately 50% of the maximum absorbance signal for the unirradiated sample.

Results

30 Lyophilized samples containing no stabilizer retained 50% of antibody avidity following irradiation with 45 kGy gamma irradiation. This is in contrast to previous results in which 45 kGy of gamma radiation destroyed essentially all the activity of immunoglobulin when it was irradiated in

solution. Thus, it is apparent that the reduction in residual water content by lyophilizing afforded significant protection on its own protein.

The addition of sodium ascorbate provided full recovery of activity after irradiation of the sample. Both methionine and lipoic acid provided significant recovery of activity (76-83%) of activity
5 after irradiation as compared to the unirradiated sample. The results are shown in Figures 1 and 2.

Example 14

In this experiment the protective effects of certain stabilizers were evaluated using lyophilized anti-insulin monoclonal antibody exposed to 45 kGy of low dose gamma irradiation. The
10 stabilizers tested were: sodium ascorbate, N15 acetyl cysteine, glutathione and mixtures of urate/trolox and ascorbate/urate/trolox.

Method

In 3 ml glass vials, 1.0 ml total volume was lyophilized containing 100 µg anti -insulin
15 monoclonal anti-body, 10 mg bovine serum albumin (1%) and either no stabilizer or the stabilizer of interest. The samples were stoppered under vacuum. Samples were irradiated with gamma radiation (45 kGy total dose, dose rate 1.83 kGy/hr, temperature 4°C) and then reconstituted with 1.0 ml water.

Antibody binding activity of independent duplicate samples was determined by a standard
20 ELISA protocol: Maxisorb plates were coated overnight with 2.5 µg/ml insulin antigen. Three-fold serial dilutions of antiinsulin utAh samples starting at 5 µg/ml were used. Goat anti-mouse Ig conjugated to phosphatase was used at 50 µg/ml. Binding activity was determined by absorbance at 405-620nm.

Relative protection was determined using a parallel line analysis software package (PLA
25 1.2 from Stegmann Systemberatung).

Results

Lyophilized samples containing no stabilizer retained 70% of antibody avidity following irradiation with 45 kGy gamma irradiation. This is in contrast to previous results in which 45 kGy of
30 gamma radiation destroyed essentially all the activity of immunoglobulin when it was irradiated in solution. Thus, it is apparent that the reduction in residual water content by lyophilizing afforded significant protection on its own protein.

The presence of sodium ascorbate increased recovery by 20%, i.e. such that there is 90%

avidity recovered after irradiation. The remaining stabilizers resulted in recovery of 77-84% of avidity. The results are shown in Figures 3A-3C.

Example 15

5 In this experiment, the protective effects of primary lyophilizing (which leaves a relatively "high moisture" content in the product) and secondary lyophilizing (which results in a product with relatively "low moisture") on the sensitivity of a monoclonal antibody were determined.

Methods

10 In 3 ml glass vials, 1.0 ml total volume was lyophilized containing 100 µg anti-insulin monoclonal anti-body, 10mg bovine serum albumin (1%) and either no stabilizer or 100 mM of sodium ascorbate. The samples were stoppered under vacuum. Samples were irradiated with gamma radiation (45 kGy total dose, dose rate between 2.03 and 2.13 kGy/hr, temperature 4°C) and then reconstituted with 1.0 ml water.

15 Antibody binding activity of independent duplicate samples was determined by a standard ELISA protocol: Maxisorb plates were coated overnight with 2.5 µg/ml insulin antigen. Three-fold serial dilutions of antiinsulin mAb samples starting at 5 µg/ml were used. Goat anti-mouse Ig conjugated to phosphatase was used at 50 ng/ml. Binding activity was determined by absorbance at 405-620nm.

20

Results

In the absence of a stabilizer, there was better recovery of the anti-insulin mAb after irradiation from the samples that had undergone the secondary "low moisture" drying cycle, i.e. a lower total moisture content in the absence of a stabilizer improved recovery.

25 In the presence of the stabilizer, however, there was very good recovery of antibody activity after 45 kGy irradiation, irrespective of whether the sample had undergone only the primary "high moisture" drying cycle or had also undergone the secondary "low moisture" drying cycle. The results of this experiment are shown in Figure 4.

Example 16

30 In this experiment, the protective effect of lyophilizing and/or an added stabilizer on the activity of Factor VII was determined. The stabilizers tested were; sodium ascorbate; sodium urate; trolox; ascorbate/trolox mixtures; ascorbate/urate/trolox mixtures; urate/trolox mixtures;

ascorbate/urate mixtures.

Methods

5 Samples were lyophilized and stoppered under vacuum. Samples were irradiated with gamma radiation (45 kGy total dose, dose rate 1.9 kGy/hr, temperature 4°C) and then reconstituted with water. Measurement of Factor VIII activity in the samples was determined in a one-stage clotting assay using an MLA Electra 1400C Automatic Coagulation Analyzer.

Results

10

In the absence of a stabilizer, there was good recovery of Factor VIII activity after irradiation of the lyophilized sample (69-88% of unirradiated control). In the presence of a stabilizer, there was similar recovery of Factor VIII activity after irradiation (69-89% of unirradiated control).

15 The combination of a stabilizer and lyophilizing, however, provided a recovery of Factor VIII of between 83-90% of the unirradiated control (sodium ascorbate + lyophilizing: 90% recovery; trolox + lyophilizing: 84% recovery; and sodium urate + lyophilizing: 83%). The results are shown in Figure 5.

Example 17

20

In this experiment, the protective effects of certain stabilizers were evaluated using liquid or lyophilized antithrombin III (AT III) exposed to 25 kGy of low dose gamma irradiation. The stabilizer tested was sodium ascorbate (200 mM).

Method

25

AT III was either irradiated alone or in the presence of ascorbate as a stabilizer. Mixing with the stabilizer was accomplished by either: (i) mixing the AT III and the stabilizer as liquids and then lyophilizing the mixture and stoppering under vacuum; or (ii) mixing the AT III and the stabilizer while both were dry powders (i.e. after each was lyophilized separately).

30

After irradiation (25 kGy total dose, 1.8 kGy/hr rate), the lyophilized powder antithrombin III (Sigma A 9141, lot 1 13H9316) + ascorbate was reconstituted to a concentration of 40 U/ml with water. Following irradiation, both the liquid and reconstituted dry powder AT III samples (+ ascorbate) were then diluted to 20 U/ml in water. Thrombin (1 U/ml) and heparin (800 U/ml) solutions in water were prepared.

In a pre-chilled 96-well plate assay, 2-fold serial dilutions of the AT III samples were

prepared. Heparin (25 μ l of 800 U/ml solution) or water was added to each well, followed by incubation at 37°C: Thrombin (50 μ l of 1 U/ml solution) was added, again followed by incubation at 37°C.

100 μ l of 1600 μ M thrombin substrate in water was then added (final concentration of substrate was 800 μ M), followed by incubation at ambient temperature. Activity was determined by measuring absorbance between 405-620nm at fixed times following substrate addition.

Results

Liquid AT III lost all thrombin inhibitory activity in the absence of a stabilizer when irradiated at 25 kGy of low rate gamma irradiation. The presence of sodium ascorbate, however, maintained 55-66% of liquid AT III activity following irradiation.

Dry powder AT III lost only 43% of activity in the presence of a dry powder stabilizer when irradiated at 25 kGy of low dose gamma irradiation.

The results of this experiment are shown in Figure 6.

15

Example 18

In this experiment, the protective effect of certain stabilizers on the activity of lyophilized anti-insulin monoclonal antibody was determined. The stabilizers tested were; sodium ascorbate; trolox/urate/ascorbate mixtures; Nacetyl cysteine and glutathione.

20

Methods

Anti-insulin monoclonal antibody supplemented with 1% of human serum albumin (and, optionally, 5% sucrose) was lyophilized, stoppered under vacuum, and irradiated (total dose 45 kGy; dose rate between 1.83 and 1.88 kGy/hr). Antibody binding activity was determined using the standard ELISA protocol described above.

25

Results

Irradiation of lyophilized anti-insulin mAb supplemented with 1% HSA to a dose of 45 kGy resulted in an average loss of avidity of about 33%. The addition of the following stabilizers significantly improved recovery: 20mM sodium ascorbate (100% recovery); 200 μ M trolox] 1.5 mM urate/20 mM ascorbate (87% recovery); 20 mM N-acetyl cysteine (82% recovery) and 20 mM glutathione (76% recovery).

30

The addition of 5% sucrose to the lyophilized mAb containing 1% HSA 15 resulted in an

average loss of avidity of about 30% when irradiated to a dose of

45 kGy. The addition of the following stabilizers significantly improved recovery: 20mM sodium ascorbate (88% recovery); 200 μ M trolox/ 1.5mM urate/20 mM ascorbate (84%) recovery); 20 mM N-acetyl cysteine (72% recovery) and 20 mM glutathione (69% recovery).

5 The results of these experiments are shown in Figures 7-14.

Example 19

In this experiment, the protective effect of stabilizers (ascorbate) on the activity of lyophilized anti-insulin monoclonal antibody was determined when the sample was irradiated at a
10 high dose rate (30 kGy/hr).

Methods

Anti-insulin monoclonal antibody was lyophilized and irradiated at a rate of 30 kGy/hr (total dose 45 kGy). Antibody binding activity was determined using the standard ELISA protocol
15 described above.

Results

Irradiation of lyophilized anti-insulin mAb to a dose of 45 kGy resulted in an average loss of activity of about 32%. The addition of 20mM sodium ascorbate provided 85% recovery of avidity
20 compared to an unirradiated sample.

The results are shown in Figure 15.

Example 20

In this experiment, lyophilized thrombin was irradiated in the presence of a stabilizer.
25

Method

Low dose rate samples were gamma irradiated at ambient temperature at a dose rate of 0.326 kGy/hr for a total dose of 45 kGy. High dose rate samples were gamma irradiated at ambient temperature at a dose rate of 30 kGy/hr for a total dose of 45 kGy.

30 Following irradiation, all samples were reconstituted with 500 μ l of 50% glycerol solution to a concentration of 100 U/ml and then diluted to 0.5 U/ml. Thrombin activity was then determined by a standard chromogenic assay utilizing a SAR-Pro-Arg-PNA substrate.

Thrombin Vmax and Km values were determined by Sigma Plot 2000 using the singular

rectangular hyperbolic fit equation for each averaged set of data. Thrombin activity was also determined using a clotting time assay performed on an MLA 1400C analyzer.

Results

5 The calculated V_{max} from thrombin irradiated at 30 kGy/hr at ambient temperature was 0.216, as compared to a V_{max} of 0.287 for its unirradiated control, indicating a 77% recovery of thrombin activity.

 The calculated V_{max} from thrombin irradiated at 0.326 kGy/hr at ambient temperature was 0.189, as compared to a V_{max} of 0.264 for the unirradiated control, indicating a 72% recovery of
10 thrombin activity. A clotting time assay performed on the low dose sample yielded a 74% relative potency compared to the unirradiated control.

 The results of this experiment are shown in Figure 16.

Example 21

15 In this experiment, an IgM monoclonal antibody specific for murine IgG3 was irradiated at a low dose rate in the presence or absence of a stabilizer.

Method

 Liquid rat anti-murine IgG2 monoclonal IgM antibody (in a PBS buffer with 10 mM sodium
20 azide; concentration of antibody was 666 ng/ μ l) was irradiated at a rate of 1.8 kGy/hr to a total dose of either 10 kGy or 45 kGy. Samples either contained no stabilizer or a stabilizer mixture containing 20 mM citrate, 300 μ M urate and 200 mM ascorbate.

 Antibody activity was analyzed by standard ELISA protocol using murine IgG3 as the coating antigen and a phosphatase-conjugated anti-rat IgM detection antibody.

25

Results

 Liquid samples containing no stabilizer lost all functional antibody activity following irradiation with either 10 kGy or 45 kGy gamma irradiation. The presence of a stabilizer mixture, however, provided full recovery of activity following irradiation with 10 kGy gamma radiation and
30 88% recovery of activity following irradiation with 45 kGy gamma radiation. The results of this experiment are shown graphically in Figure 17.

Example 22

In this experiment, lyophilized and liquid samples of albumin were irradiated with gamma irradiation.

5 Method

Samples were irradiated with a total dose of either 10 kGy or 40 kGy gamma radiation. Following irradiation, the lyophilized samples were reconstituted with 1.1 ml of assay buffer (50 mM Tris, pH 8.8; 50 mM NaCl; 0.1%PEG 8000).

10 Samples (lyophilized and liquid) were analyzed by size-exclusion column chromatography (TSKge1 G4000SWxl 30 cm x 7.8 mm; elution buffer 0.1 M sodium phosphate pH 6.5/0.1 M sodium sulfate; flow rate 1 ml/min) with a UV detection system set at 280nm.

Results

15 No degradation products were observed in the liquid or lyophilized samples of albumin irradiated with a total dose of 10 kGy gamma radiation. Although some degradation product was observed in the liquid samples of albumin irradiated with a total dose of 40 kGy gamma radiation, no such degradation was observed in the lyophilized samples irradiated with a total dose of 40 kGy gamma radiation. The chromatographic results of this experiment are shown in Figure 18.

20 Experiment 23

This experiment measured the sensitivity of prions (transmissible spongiform encephalopathy agents) to ionizing radiation at low dose rates.

Method

25 0.3 ml of phosphate buffered saline containing a 10% homogenate (brains collected from golden Syrian hamsters in the terminal stages of scrapie infection) was added to 29.7 ml of albumin in a 50 ml polypropylene tube. Samples were irradiated with a total dose of either 30 kGy or 55 kGy (control samples were not irradiated).

30 Weanling golden Syrian hamsters were inoculated intracerebrally with 50 μ l of undiluted sample. All animals were then evaluated for signs of scrapie disease and scored for the appearance of a wobbling gait, failure to rear and terminal condition (at which point they were euthanized). The days post inoculation for each sign for each animal was calculated.

Results

Irradiation at the higher total dose (55 kGy) provided a thirteen to fifteen day delay in the median incubation times compared to the unirradiated control for any of the three symptomatic endpoints, which is equivalent to an approximately 2 log₁₀ID₅₀ reduction in the titer of the pathogen. Irradiation at the lower total dose (30 kGy) provided an eight to thirteen day delay in incubation time, which is equivalent to an approximately 1 log₁₀ID₅₀ reduction in the titer of the pathogen. This was still significantly longer than the unirradiated control.

Linear regression analysis of the data results in 95% confidence intervals that indicate that the actual reduction in pathogen levels may be as high as a 3.5 log₁₀D₅₀ reduction in the titer of the pathogen.

Experiment 24

This experiment evaluated the protective effect of lyophilizing and/or the presence of a stabilizer on thrombin activity following irradiation with 45 kGy gamma radiation.

15

Method

Samples of thrombin were prepared containing 1% bovine serum albumin and lyophilized to the desired level of moisture. Sodium ascorbate was added to a concentration of 200 mM in some samples as a stabilizer.

All samples were then irradiated with gamma radiation (45 kGy total dose rate, 2.03 to 2.13 kGy/hr at 4°C) and thrombin activity measured

Results

In the absence of stabilizer, 67% of thrombin activity was recovered from the irradiated samples that had undergone only a primary drying cycle. The addition of a stabilizer increased the recovery to 86%. The results of this experiment are shown graphically in Figure 19.

Example 25

In this experiment, the protective effects of certain stabilizers were evaluated using liquid IVIG polyclonal antibody exposed to 45 kGy of gamma irradiation (1.8 kGy/hr). The stabilizers tested were: sodium ascorbate and a mixture of sodium ascorbate and N-acetyl cysteine.

Results

Irradiated samples containing no stabilizer exhibited the following losses in activity: 1 log

with respect to rubella; 0.5-0.75 log with respect to mumps; and 1 log with respect to CMV. Irradiated samples containing sodium ascorbate or a mixture of sodium ascorbate and N-acetyl cysteine as a stabilizer exhibited no loss in activity when compared to unirradiated controls.

The results of this experiment are shown graphically in Figures 20-26.

5

Example 26

This experiment was designed to examine the effects of pH on the recovery of urokinase (liquid or lyophilized) irradiated in the presence of a stabilizer (sodium ascorbate, sodium urate or a mixture thereof).

10

Method

Urokinase (1000 U/ml) was mixed with 200 mM sodium ascorbate and/or 300 μ M in the presence of 35 mM phosphate buffer at various pHs. All tested samples were irradiated with a total dose of 45 kGy gamma radiation at a rate of 2 kGy/hr.

15

Results

The lyophilized irradiated samples containing sodium ascorbate exhibited a recovery of about 88-90% of urokinase activity across the pH range of 5.5-7.8, inclusive. The liquid irradiated samples containing sodium ascorbate exhibited a recovery of about 65-70% of urokinase activity across the pH range 5.5-7.8. The results of this experiment are shown graphically in Figure 26.

20

Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations, and other parameters without departing from the scope of the invention or any embodiments thereof. All patents and publications cited herein are hereby fully incorporated by reference in their entirety.

25

WHAT IS CLAIMED IS:

1. A method for sterilizing a biological material that is sensitive to ionizing radiation,
5 said method comprising:
- (i) reducing the residual solvent content of a biological material to a level effective to protect said biological material from said ionizing radiation;
 - (ii) lowering the temperature of said biological material to a level at or below its eutectic point or freezing point and
 - 10 (iii) irradiating said biological material with gamma radiation at an effective rate for a time effective to sterilize said biological material, wherein said biological material is a proteinaceous material produced utilizing recombinant/transgenic technology.
2. A method for sterilizing a biological material that is sensitive to ionizing radiation,
15 said method comprising:
- (i) adding to a biological material at least one stabilizer in an amount effective to protect said biological material from said ionizing radiation;
 - (ii) lowering the temperature of said biological material to a level at or below its eutectic point or freezing point; and
 - 20 (iii) irradiating said biological material with gamma radiation at an effective rate for a time effective to sterilize said biological material, wherein said biological material is a proteinaceous material produced utilizing recombinant/transgenic technology.
3. A method for sterilizing a biological material that is sensitive to ionizing radiation,
25 said method comprising:
- (i) adding to a biological material at least one stabilizer in an amount effective to protect said biological material from said ionizing radiation;
 - (ii) lowering the temperature of said biological material to a level at or below its eutectic point or freezing point; and
 - 30 (iii) irradiating said biological material with gamma radiation at a low rate for a time effective to sterilize said biological material, wherein said biological material is a proteinaceous material produced utilizing recombinant/transgenic technology.

4. A method for sterilizing a biological material that is sensitive to ionizing radiation, said method comprising:
- (i) reducing the residual solvent content of a biological material to a level effective to protect said biological material from said ionizing radiation;
 - (ii) lowering the temperature of said biological material to a level at or below its eutectic point or freezing point; and
 - (iii) irradiating said biological material with gamma radiation at a low rate for a time effective to sterilize said biological material, wherein said biological material is a proteinaceous material produced utilizing recombinant/transgenic technology.
5. A method for sterilizing a biological material that is sensitive to ionizing radiation, said method comprising:
- (i) reducing the residual solvent content of a biological material to a level effective to protect said biological material from said ionizing radiation;
 - (ii) adding to said biological material at least one stabilizer in an amount effective to protect said biological material from said ionizing radiation;
 - (iii) lowering the temperature of said biological material to a level at or below its eutectic point or freezing point; and
 - (iv) irradiating said biological material with gamma radiation at an effective rate for a time effective to sterilize said biological material, wherein steps (i), (ii) and (iii) may be performed in any order and further wherein said biological material is a proteinaceous material produced utilizing recombinant/transgenic technology.
6. The method according to claim 2 or 3, further comprising the step of reducing the residual solvent content of said biological material prior to said step of irradiating said biological material.
7. The method according to claim 6, wherein said residual solvent content is reduced by the addition of a solute.
8. The method according to claim 1, 4 or 5, wherein said residual solvent content is reduced by the addition of a solute.
9. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material is a component of blood.
10. The method according to claim 9, wherein said component of blood is a clotting

factor.

11. The method according to claim 10, wherein said clotting factor is selected from the group consisting of Thrombin, Factor II, Factor V, Factor VII, Factor VIIa, Factor VIII, Factor IX, Factor X, Factor XIII Factor XIIIa, Von Willebrand's Factor and Fibrinogen.
- 5 12. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material is selected from the group consisting of albumin, urokinase, polyclonal immunoglobulins, monoclonal immunoglobulins, and mixtures of one or more polyclonal and/or monoclonal immunoglobulins.
13. The method according to claim 12, wherein said immunoglobulins are selected from the group consisting of immunoglobulin G, immunoglobulin M, or mixtures thereof.
- 10 14. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material is a carbohydrate or polysaccharide.
15. The method according to claim 14, wherein said carbohydrate or polysaccharide is selected from the group consisting of chitin, chitosan, NOCC-chitosan and derivatives thereof.
16. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material is a product of cellular metabolism.
17. The method according to claim 1, 2, 3, 4 or 5, wherein said rate is not more than about 3.0 kGy/hour.
18. The method according to claim 1, 2, 3, 4 or 5, wherein said rate is not more than about 2.0 kGy/hour.
- 20 19. The method according to claim 1, 2, 3, 4 or 5, wherein said rate is not more than about 1.0 kGy/hour.
20. The method according to claim 1, 2, 3, 4 or 5, wherein said rate is not more than about 0.3 kGy/hour.
21. The method according to claim 1, 2 or 5, wherein said rate is more than about 3.0 kGy/hour.
- 25 22. The method according to claim 1, 2 or 5, wherein said rate is at least about 6.0 kGy/hour.
23. The method according to claim 1, 2 or 5, wherein said rate is at least about 18.0 kGy/hour.
- 30 24. The method according to claim 1, 2 or 5, wherein said rate is at least about 30.0 kGy/hour.
25. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material is maintained in a low oxygen atmosphere.
26. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material

contains at least one prion as a biological contaminant.

27. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material contains at least one virus as a biological contaminant.

28. The method according to claim 1 or 4, wherein at least one stabilizer is added to
5 said biological material prior to said step of irradiating said biological material.

29. The method according to claim 2, 3 or 8, wherein said at least one stabilizer is an antioxidant.

30. The method according to claim 2, 3 or 8, wherein said at least one stabilizer is a free radical scavenger.

10 31. The method according to claim 2, 3 or 8, wherein said at least one stabilizer is known to reduce damage due to reactive oxygen species.

32. The method according to claim 2, 3 or 8, wherein said at least one stabilizer is selected from the group consisting of: ascorbic acid or a salt or ester thereof; uric acid or a salt or ester thereof; methionine; histidine; N-acetyl cysteine; and mixtures of two or more of said
15 stabilizers.

33. The method according to claim 7, wherein said solute is a component of milk.

34. The method according to claim 8, wherein said solute is a component of milk.

35. The method according to claim 1, 2, 3, 4 or 5, wherein said irradiation is constant throughout said sterilization.

20 36. The method according to claim 1, 2, 3, 4 or 5, wherein said irradiation is not constant throughout said sterilization.

37. The method according to claim 1, 2, 3, 4 or 5, wherein said proteinaceous material is selected from the group consisting of: (a) proteins/peptides produced from tissue culture; and (b) materials extracted or isolated from animal tissue or plant matter.

25 38. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material contains at least one bacteria as a biological contaminant.

39. The method according to claim 1, 2, 3, 4 or 5, wherein said biological material contains at least one parasite as a biological contaminant.

30 40. The method according to claim 1, 2, 3, 4 or 5, wherein said proteinaceous material is processed/purified prior to said irradiating.





Fig. 1



3/28

010401dm 039 Effect of Gamma Irradiation on Freeze-dried Anti-Insulin Mab in presence of Various Stabilizers (and 1% BSA)




Fig. 3A




Fig. 3B

5/28

010401alm 039 Effect of Gamma Irradiation on Freeze-dried Anti-Insulin Mab in presence of Various Stabilizers (and 1% BSA)





Fig. 3C

6/28



7/28

Comparison of Relative Potency of Frozen FVIII
± Stabilizers




Fig. 5

8/28

011701alm 040 Effect of Gamma Irradiation on Liquid and Dry Antithrombin III(\pm 200mM Ascorbate)





Fig. 6

9/28

01.29.01 Gamma Irradiation of Freeze-dried Anti-Insulin Monoclonal Antibody in the Absence or Presence of 20mM Ascorbate (1% HSA)



[Anti-Insulin MAb], µg/mL

Fig. 7

10/28

01.29.01 Gamma Irradiation of Freeze-dried Anti-Insulin Monoclonal Antibody in the Absence or Presence of TUA Cocktail (200 μ M Trolox, 1.5mM Urate, 20mM Ascorbate, 1% HSA)




Fig. 8

11/28

01.29.01 Gamma Irradiation of Freeze-dried Anti-Insulin Monoclonal Antibody
in the Absence or Presence of 20 mM N-Acetyl-Cysteine (1% HSA)




Fig. 9

12/28

01.29.01 Gamma Irradiation of Freeze-dried Anti-Insulin Monoclonal Antibody in the Absence or Presence of 20 mM Reduced Glutathione (1% HSA)




Fig. 10

02.01.01 Gamma Irradiation of Freeze-Dried Anti-Insulin Monoclonal Antibody
Irradiated in the Absence or Presence of 20 mM Ascorbate
(1% HSA, 5% Sucrose)




Fig. 11

02.01.01 Gamma Irradiation of Freeze-Dried Anti-Insulin Monoclonal Antibody
in the Presence of TUA Cocktail

(200 µM Trolox, 1.5 mM Urate, 20 mM Ascorbate; 1% HSA, 5% Sucrose)




Fig. 12

15/28

02.01.01 Gamma Irradiation of Freeze-Dried Anti-Insulin Monoclonal Antibody
in the Presence of 20 mM N-Acetyl-L-Cysteine
(1% HSA, 5% Sucrose)




Fig. 13

16/28

02.01.01 Gamma Irradiation of Freeze-Dried Anti-Insulin Monoclonal Antibody
in the Presence of 20 mM Reduced Glutathione
(1% HSA, 5% Sucrose)




Fig. 14

17/28

(02.20.01) Freeze-dried Anti-Insulin Monoclonal Antibody Irradiated at a High Dose Rate (30 kGy/h) in the Absence or Presence of 20 mM Ascorbate (011201.tag.046)





Fig. 15

010901aimi 044 Effect of Dose Rate on Freeze-Dried Thrombin⁹
in the presence of Ascorbate



Vmax
30kGy/hr 45/0 = 77% recovery
0.33kGy/hr 45/0 = 72% recovery

Fig. 16

19/28

0.8.28.00 Irradiation of Rat IgM Monoclonal to Mouse IgG3 in the Absence or Presence of Scavenger Cocktail
(20mM Citrate, 300 μ M Urate, 200 mM Ascorbate)




Fig. 17




Fig. 18

(121800rwa014)Effect of 45kGy-irradiation on Freeze Dried Thrombin (Primary Dry Cycle Only)
1%Albumin and +/- 200mM Ascorbate




Fig. 19




Fig. 20




Fig. 21




Fig. 22

25/28




Fig. 23




Fig. 24




Fig. 25




Fig. 26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/22450

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(7) : A61L 2/08
 US CL : 422/22; 435/2
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 422/22; 435/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 NONE


C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,730,933 A (PETERSON) 24 March 1998 (24.03.1998), see entire document.	1, 2, 5-9, 12, 25-32, 35-40
Y --- A	US 6,171,549 B1 (KENT) 09 January 2001 (09.01.2001), see entire document.	3, 4, 10, 11, 13-20, 3, 4, 10, 11, 17-20
Y --- A	US 5,712,086 A (HOROWITZ et al) 27 January 1998 (27.01.1998), see entire document.	13-16 21-24, 33, 34

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 04 November 2003 (04.11.2003)	Date of mailing of the international search report 28 NOV 2003
--------------------------------------------------------------------------------------------	--------------------------------------------------------------------------

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Authorized officer Leigh McKane  Telephone No. 703-308-0661
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------